comparemela.com

Latest Breaking News On - Maher masoud - Page 3 : comparemela.com

MaxCyte Inc (MXCT) Reports Mixed Financial Results for Q4 and Full Year 2023

Despite Challenges, Company Reiterates 2024 Guidance

Maher masoudMaxcyte incAnalysis of company performanceFinancial performanceMedical devicesRevenue generatedScore revenueMaxcyte incCore businessTotal revenueRevenue growth

On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough

On the Charge: MaxCyte Celebrates Role in Sickle Cell Therapy Breakthrough
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

United statesCharles riverJudah folkmanSergey dzekunovDoug doerflerJohn holadayMaher masoudJimi olaghereJames bradyJim bradyVivien sheehanHuman genome sciencesPhd emory university school of medicineVertex pharmaceuticalsVictoria grayDrug administration

MaxCyte signs licencing deal with cell therapy company Wugen

MaxCyte Inc - Maryland, US-based provider of cell engineering platform technologies developing next-generation cell therapeutics - Signs strategic platform licence with Wugen Inc, a US-based.

United statesHugh cameronMaher masoudAlliance news ltdMaxcyte incAlliance newsWugen incMaxcyte chief executive officer maher masoudAll rights

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers -January 30, 2024 at 08:06 am EST

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancersROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 .

United kingdomMary jane elliottMark lewisPanmure gordonDavid deuchlerChris welshRupert deardenKumar srinivasanMaher masoudEmma earl freddy crossleyChristine fanelleMaxcyte incDrug administrationWugen incGilmartin groupFlow electroporation

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood.

United kingdomNorth carolinaUnited statesWestern australiaNew south walesMary jane elliottPanmure gordonRupert deardenDavid deuchlerChris welshMatt wrightMaher masoudYoutube imugenelimitedEmma earl freddy crossleyLeslie chongImugene limited contacts

vimarsana © 2020. All Rights Reserved.